# Longevity Health Holdings, Inc.: overview XAGE · OTC · CIK 1842939 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/xage.md) · [Financials](/companies/xage/financials.md) · [Filings](/companies/xage/filings.md) · [Insiders](/companies/xage/insiders.md) Latest reported revenue: [$396.0k](/filings/0001437749-26-028043.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-028043). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [20.5](/filings/0001193125-25-283127.md) | [17.5 d](/filings/0001193125-26-134698.md) | [510](/filings/0001193125-26-224428.md) | [504](/filings/0001437749-26-028043.md) | [426](/filings/0001193125-25-283127.md) | [473 d](/filings/0001193125-26-134698.md) | [392](/filings/0001193125-26-224428.md) | [396](/filings/0001437749-26-028043.md) | | Gross margin | % | [76.4%](/filings/0001193125-25-283127.md) | [93.0% d](/filings/0001193125-26-134698.md) | [52.9%](/filings/0001193125-26-224428.md) | [60.1%](/filings/0001437749-26-028043.md) | [59.8%](/filings/0001193125-25-283127.md) | [56.6% d](/filings/0001193125-26-134698.md) | [60.5%](/filings/0001193125-26-224428.md) | [59.5%](/filings/0001437749-26-028043.md) | | Operating margin | % | [(6919.4%)](/filings/0001193125-25-283127.md) | [(5760.5%) d](/filings/0001193125-26-134698.md) | [(295.2%)](/filings/0001193125-26-224428.md) | [(369.1%)](/filings/0001437749-26-028043.md) | [(345.4%)](/filings/0001193125-25-283127.md) | [(480.2%) d](/filings/0001193125-26-134698.md) | [(339.1%)](/filings/0001193125-26-224428.md) | [(182.9%)](/filings/0001437749-26-028043.md) | | Net margin | % | [(14028.4%)](/filings/0001193125-25-283127.md) | [(5230.8%) d](/filings/0001193125-26-134698.md) | [(295.1%)](/filings/0001193125-26-224428.md) | [(374.6%)](/filings/0001437749-26-028043.md) | [(335.7%)](/filings/0001193125-25-283127.md) | [(440.4%) d](/filings/0001193125-26-134698.md) | [(365.5%)](/filings/0001193125-26-224428.md) | [(475.6%)](/filings/0001437749-26-028043.md) | | Diluted EPS | $ per share | [(4.13)](/filings/0001193125-25-283127.md) | not reported | [(1.52)](/filings/0001193125-26-224428.md) | [(1.56)](/filings/0000950170-25-108973.md) | [(0.83)](/filings/0001193125-25-283127.md) | not reported | [(0.75)](/filings/0001193125-26-224428.md) | not reported | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | [(306) d](/filings/0001193125-26-134698.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | [0.0](/filings/0000950170-25-087485.md) | [50.3](/filings/0001193125-26-134698.md) | [1,913](/filings/0001193125-26-134698.md) | | Gross margin | % | not reported | not reported | [87.4%](/filings/0001193125-26-134698.md) | [57.2%](/filings/0001193125-26-134698.md) | | Operating margin | % | not reported | not reported | [(9933.8%)](/filings/0001193125-26-134698.md) | [(371.6%)](/filings/0001193125-26-134698.md) | | Net margin | % | not reported | not reported | [(20605.5%)](/filings/0001193125-26-134698.md) | [(361.0%)](/filings/0001193125-26-134698.md) | | Diluted EPS | $ per share | [(5.47)](/filings/0000950170-24-038992.md) | [(1.46)](/filings/0000950170-25-087485.md) | [(14.56)](/filings/0001193125-26-134698.md) | [(4.83)](/filings/0001193125-26-134698.md) | | Free cash flow | $k | [(3,436)](/filings/0000950170-24-038992.md) | [(8,379)](/filings/0000950170-25-087485.md) | not reported | [(3,343)](/filings/0001193125-26-134698.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xage/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [DRW Securities, LLC](/funds/1481986.md) | 2026-06-30 | $3.7k | 14,154 | | Unchanged | | [Ancora Advisors LLC](/funds/1446114.md) | 2026-06-30 | $14 | 2,791 | | Unchanged | ## Recent filings [All 338 filings](/companies/xage/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-08 | 08:00 ET | [8-K](/filings/0001437749-26-029755.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-029755 | | 2026-09-04 | 17:03 ET | [8-K](/filings/0001437749-26-029714.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001437749-26-029714 | | 2026-08-17 | 09:57 ET | [8-K](/filings/0001437749-26-028120.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-028120 | | 2026-08-14 | 17:02 ET | [10-Q](/filings/0001437749-26-028043.md) | Quarterly report, period 2026-06-30 | 0001437749-26-028043 | | 2026-08-14 | 16:11 ET | [8-K](/filings/0001437749-26-028011.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-028011 | | 2026-06-04 | 16:30 ET | [8-K](/filings/0001193125-26-257520.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-257520 | | 2026-05-15 | 17:53 ET | [10-Q](/filings/0001193125-26-224428.md) | Quarterly report, period 2026-03-31 | 0001193125-26-224428 | | 2026-04-08 | 21:52 ET | [SCHEDULE 13D](/filings/0001423603-26-000008.md) | Ownership report, active investor | 0001423603-26-000008 | | 2026-03-31 | 16:30 ET | [10-K](/filings/0001193125-26-134698.md) | Annual report, period 2025-12-31 | 0001193125-26-134698 | | 2026-03-17 | 08:30 ET | [8-K](/filings/0001193125-26-109472.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-109472 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-134698.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/18389bdf-434d-443a-b694-cdc444751b9e) ## About the filer - CIK: 1842939 - Tickers: XAGE, XAGEW - Exchange: OTC - SIC code: 2840 Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.